On the other hand, additional studies in this field have identified the Burton tyrosine kinase (BTK) as a target upstream NF-ĸB, which could become a promising therapeutic approach since different BTK inhibitors have already proven their safety and have been approved for the treatment of different hematological malignancies [114]. The gene discussed is BTK; the disease is hematologic disorder.